Rachel Anderson, DO
Family Medicine · Thomasville, GANPI 1407383805
Payments from drug & device makers
Across 328 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$696
- Pfizer$612
- GSK$556
- Novo Nordisk$544
- Boehringer Ingelheim$481
- Bayer$466
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $696 |
| Pfizer | 40 | $612 |
| GSK | 42 | $556 |
| Novo Nordisk | 30 | $544 |
| Boehringer Ingelheim | 24 | $481 |
| Bayer | 24 | $466 |
| Lilly USA, LLC | 27 | $414 |
| AstraZeneca | 18 | $326 |
| Teva Pharmaceuticals USA, Inc. | 14 | $266 |
| Novartis | 10 | $242 |
| Exact Sciences | 10 | $168 |
| Amgen | 9 | $154 |
| Merck | 5 | $84 |
| Astellas Pharma US Inc | 4 | $77 |
| Johnson & Johnson | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Corcept Therapeutics | 2 | $42 |
| Insulet Corporation | 2 | $41 |
| Dexcom, Inc. | 2 | $36 |
| Vertex | 1 | $22 |
| CGG Medical Inc | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 4 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Smith+Nephew | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$117
- VRAYLAR$115
How this compares
$5,644 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $90,669 |
| LinzessLinaclotide | 55 | $67,390 |
| RybelsusSemaglutide | 42 | $56,760 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $48,567 |
| FarxigaDapagliflozin Propanediol | 29 | $45,691 |
| JardianceEmpagliflozin | 40 | $38,409 |
| EliquisApixaban | 49 | $36,636 |
| JanuviaSitagliptin Phosphate | 30 | $34,568 |
| QuliptaAtogepant | 26 | $33,556 |
| MounjaroTirzepatide | 26 | $30,443 |
| VraylarCariprazine Hcl | 13 | $21,001 |
| UbrelvyUbrogepant | 17 | $18,157 |
| TradjentaLinagliptin | 17 | $12,615 |
| XareltoRivaroxaban | 18 | $12,416 |
| PremarinEstrogens, Conjugated | 19 | $8,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $544 | $147,429125 claims |
| AbbVieLinzess, Qulipta, Vraylar, Ubrelvy | $696 | $140,103111 claims |
| AstraZenecaFarxiga, Symbicort | $326 | $52,25948 claims |
| Boehringer IngelheimJardiance, Tradjenta | $481 | $51,02557 claims |
| GSKTrelegy Ellipta | $556 | $48,56736 claims |
| PfizerEliquis, Premarin | $612 | $45,40868 claims |
| MerckJanuvia | $84 | $34,56830 claims |
| Lilly USA, LLCMounjaro | $414 | $30,44326 claims |
| Johnson & JohnsonXarelto | $57 | $12,41618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Thomasville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.